Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Suzanne Jorey

Internal Medicine West Springfield, MA Medical Doctor

NPI 1730157298 CMS profile 726252

46 Daggett Dr, Suite 3B, West Springfield, MA 01089

Open in the dashboard

General payments

$3,378

164 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Suzanne Jorey of West Springfield, MA is reported in the CMS Open Payments database as having received $3,378 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $953 43
2024 General $1,305 62
2023 General $755 38
2022 General $187 10
2021 General $143 9
2020 General $35 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suzanne Jorey
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Suzanne Jorey were reported at $953. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Suzanne Jorey Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $35 $119 $33–$402 $114
2021 $143 $135 $37–$521 $132
2022 $187 $141 $42–$496 $149
2023 $755 $149 $45–$519 $160
2024 $1,305 $154 $47–$537 $164
2025 $953 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $527 23 payments
  2. Abbott Laboratories $434 21 payments
  3. Pfizer Inc. $340 20 payments
  4. Lilly USA, LLC $289 16 payments
  5. Janssen Pharmaceuticals, Inc $274 11 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $270 15 payments
  7. AbbVie, Inc. $228 11 payments
  8. Sumitomo Pharma America, Inc. $225 9 payments
  9. Astellas Pharma US Inc $215 9 payments
  10. Novo Nordisk Inc $144 8 payments
  11. Other $433 21 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,367 163 payments
  2. Education $12 1 payment
Products named General payments · program years 2020–2025
  1. FreeStyle Libre 3 $386 19 payments
  2. ELIQUIS $262 16 payments
  3. NURTEC ODT $247 15 payments
  4. GEMTESA $225 9 payments
  5. Veozah $215 9 payments
  6. XARELTO $200 9 payments
  7. JARDIANCE $191 11 payments
  8. PAXLOVID $140 9 payments
  9. VRAYLAR $126 6 payments
  10. ZEPBOUND $105 4 payments
  11. Other $1,414 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 162 drugs

Part D claims

13,239

Median for Internal Medicine: 777

Drug cost

$1,072,325

Median for Internal Medicine: $73,373

Branded share of claims

18.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 309 $292,753
Ozempic Semaglutide Brand 92 $101,054
Januvia Sitagliptin Phosphate Brand 73 $83,244
Xarelto Rivaroxaban Brand 67 $68,125
Farxiga Dapagliflozin Propanediol Brand 63 $64,818
Jardiance Empagliflozin Brand 36 $44,336
Mounjaro Tirzepatide Brand 26 $38,938
Trulicity Dulaglutide Brand 26 $29,931
Oxycontin Oxycodone Hcl Brand 11 $29,422
Rybelsus Semaglutide Brand 20 $21,241

The 10 drugs with the highest cost, of 162 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$265,562

Of which drugs: $29,688

Medicare patients

723

Average age 78

Services billed

5,063

495 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 52%
Atrial fibrillation 23%
Chronic kidney disease 22%
Depression 22%
Diabetes 20%
Ischemic heart disease 20%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 66 66 $19,176
Vaccine for influenza for injection into muscle 90662 Office 109 109 $8,908

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $137
  • Lilly USA, LLC $14
$150 36 —
XARELTO
  • Janssen Pharmaceuticals, Inc $110
$110 67 —
GEMTESA
  • Sumitomo Pharma America, Inc. $103
$103 13 —
ZEPBOUND
  • Lilly USA, LLC $88
$88 — —
Veozah
  • Astellas Pharma US Inc $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record